REV Group Reaffirms FY23 Sales Outlook Of $2.3B-$2.5B Vs. $2.37B Estimate
Adjusted EBITDA of $110-$130 million, and Adjusted Net Income of $42-$60 million; Updates outlook for net income to $13-$32 million
Life Time Expects Q1 FY23 Sales Of $505M-$510M Vs. $509.8M Estimate; Reiterates FY23 Revenue Guidance Of $2.2B-$2.3B Vs. $2.25B Estimate
Adjusted EBITDA For Q1 FY23 Expected To Be $108M-$110M.
Adjusted EBITDA For FY23 is Expected To Be $440M-$4600M.
Other 2023 Outlook Items
Plans to open 10 athletic country clubs in
Adidas Q4 Revenue Declines 1%, Slashes Dividend By 78% Amid Kanye West Split Impact
Adidas AG (OTC:ADDYY) reported a 1% decline in currency-neutral revenues for fourth-quarter FY22. The decrease in revenue was due to…
What’s Going On With Globalstar Stock?
Globalstar, Inc. (NASDAQ: GSAT) shares are trading flat at $1.20 during Tuesday's after-hours session after the company announced it had
Aquestive Therapeutics Sees FY23 Revenue $37M-$41M Vs $37.83M Est.
2023 Outlook
Aquestive is providing its full year 2023 financial outlook.
The Company expects:
Guidance
Total revenue (in millions)
$37 to $41
Non-GAAP adjusted EBITDA
What’s Going On With ThredUp Shares Today?
ThredUp Inc. (NASDAQ: TDUP) shares are trading higher after the company reported better-than-expected Q4 sales and issued strong Q1 guidance.
Anghami Reports 35.6% Revenue Growth In Preliminary Unaudited 2022 Results, With Focus On Continued Efficiency And Profitability For 2023; Total Year Revenue $48.1M
Total unaudited revenue of $48.1 million for 2022, an increase of 35.6% year-on-year
Ended 2022 with 1.52 million paying subscribers, an increase of 21% compared to 2021,
BlackSky Records 69% Increase In Q4 Revenues; Expects Positive Adjusted EBITDA In 4Q23
BlackSky Technology Inc (NYSE:BKSY) reported fourth-quarter revenue growth of 69% year-over-year to $19.42 million, missing the consensus of $19.62 million.…
Synaptogenix Provides Corporate Update And Outlines Potential Business Opportunities; Remains Well-Funded With ~$37.5M In Cash As Of Year-End 2022 And A Relatively Low Cash Burn Rate
Announces encouraging secondary endpoint results from NIH-sponsored Phase 2 clinical trial of Bryostatin-1 in advanced Alzheimer's disease patients
Maintains strong financial position with approximately $37.5